The research and development of mitochondrial genome-based products company Mitomics and Bostwick Laboratories, a leading full-service medical laboratory at the forefront of urologic pathology, has entered into a non-exclusive agreement to expand the sales and marketing of Mitomics’ flagship product, the Prostate Core Mitomic Test (PCMT), across the United States. Bostwick Laboratories will market the Mitomic Technology under the name ProstaClear Mitomic Test (PCMT).
PCMT is a highly advanced, proprietary test based on the science of mitochondrial DNA (mtDNA). Using previously obtained prostate biopsy tissue, PCMT can determine the presence of malignant cells via a cancerization field effect by detecting underlying molecular alterations in normal-appearing tissue. This is all performed quickly and easily with a simple lab test.
“Our partnership with Bostwick Laboratories is very timely and builds upon our strong momentum following the launch of PCMT earlier this year,” said Robert Poulter, president and chief executive officer, Mitomics. “As we continue to receive positive feedback from the physician community on PCMT and are, in fact, expanding our processing capacity to meet increasing demand for the test, Bostwick Laboratories’ established network within the urologic pathology community will be invaluable, providing patients and physicians greater access to our leading prostate cancer testing technology. Notably, our partnership allows a seamless test requisition and reporting process with those urological practices that have known and trusted Bostwick Laboratories for many years.”
Mitomics’ PCMT is a highly advanced test, based on the science of mitochondrial DNA (mtDNA), that accurately identifies a biomarker that can indicate the presence of cancerous cells using previously obtained prostate biopsy tissue. PCMT takes advantage of a tumour’s cancerization field effect to identify molecular changes and enable detection of missed tumors. The test’s sensitivity of 84 per cent and ability to accurately rule out prostate cancer with a negative predictive value of 91 per cent can provide reliable information to patients confronted with a possible prostate cancer diagnosis.